Biogen Inc.
BIIBDrug Manufacturers - General
$249.65+2.29%As of Oct 29vs prior close
- Market cap
- $36.9B
- P/E (TTM)
- 105.8×
- P/E (FY1)
- 20.2×
- From 52W high
- −1.65%
- EPS (LTM)
- $2.32
- Revenue (LTM)
- $10.3B
- Net margin
- 3.37%
Nomior Score
67
Steady ProfileTop 13% of the scored universe
Growth35
Quality65
Value61
Momentum92
Resilience50
Growth
−1.61%revenue a year over 9 fiscal years
YE16 $11.4BLTM $10.3B
Connections
Revenue to profitQ3 YE26
The net loss was 1% of revenue, wider by 19 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $2.8 billion
- Diluted loss per share
- $(0.14)
- Adjusted EPS
- $2.62
- EPS outlook
- $12.20 to $13.00
Total revenue rose year over year, led by strong growth in the Growth Portfolio and a first full quarter of acquired Apellis products. Earnings fell sharply, mainly because of a large acquired IPR&D and milestone charge tied to the RayThera acquisition. Biogen raised the lower end of its full-year non-GAAP EPS guidance range.
Who owns it
6funds, 3 tracked portfolios